Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in relapsed/refractory multiple myeloma
2006-000026-31Phase 2Terminated
- Sponsor
- Roche
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in multiple myeloma (MM), sponsored by Roche. Primary endpoints: Overall response rate (complete and partial response) and Safety of bevacizumab. Started Jan 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-000026-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000026-31.